TY - JOUR
T1 - Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice
AU - Lecoeur, H. F.
AU - Lagrange, P. H.
AU - Truffot-Pernot, C.
AU - Gheorghui, M.
AU - Grosset, J.
PY - 1989/1/1
Y1 - 1989/1/1
N2 - Three strains of mice (Swiss albinos, C5BL/6, C3H/OuJ) were injected intravenously with 3.7 x 106 colony forming units (CFU) of M. tuberculosis, H37RV, sensitive and resistant to antibiotics (90% of bacilli sensitive, 9% resistant of Streptomycin and 0.9% resistant to Kanamycin). Two weeks later, chemotherapy was started 6 days a week for a 6-month period with isoniazid (INH) and rifampicin (RMP). Twenty mice of each strain were killed at the end of the chemotherapy and the others were kept without antibiotics for a second 6-month follow-up period before being killed. The early multiplication of bacilli during the first 2 weeks following infection and before chemotherapy, was similar in the three strains of mice. Chemotherapy had the same apparent efficacy in the three strains of mice, nearly all the mice being cured as assessed by a negative spleen culture on Lowenstein-Jensen medium at the end of chemotherapy. But after the 6-month follow-up period, the C3H strain presented a statistically significantly higher level of positive spleen culture ('relapse') than seen in the C57BL/6 strain, and an increased number of mycobacteria per relapsing mouse spleen. It has been estimated with the help of resistant and sensitive bacilli that the relapses were due in most of the cases to the regrowth of one or very few bacilli, giving a clone. It seems that the C3H strain of mice, known to carry the Bcg-r allele of the Bcg gene, might be less able to develop a specific acquired resistance capable of stopping the delayed development of a highly virulent strain of mycobacteria.
AB - Three strains of mice (Swiss albinos, C5BL/6, C3H/OuJ) were injected intravenously with 3.7 x 106 colony forming units (CFU) of M. tuberculosis, H37RV, sensitive and resistant to antibiotics (90% of bacilli sensitive, 9% resistant of Streptomycin and 0.9% resistant to Kanamycin). Two weeks later, chemotherapy was started 6 days a week for a 6-month period with isoniazid (INH) and rifampicin (RMP). Twenty mice of each strain were killed at the end of the chemotherapy and the others were kept without antibiotics for a second 6-month follow-up period before being killed. The early multiplication of bacilli during the first 2 weeks following infection and before chemotherapy, was similar in the three strains of mice. Chemotherapy had the same apparent efficacy in the three strains of mice, nearly all the mice being cured as assessed by a negative spleen culture on Lowenstein-Jensen medium at the end of chemotherapy. But after the 6-month follow-up period, the C3H strain presented a statistically significantly higher level of positive spleen culture ('relapse') than seen in the C57BL/6 strain, and an increased number of mycobacteria per relapsing mouse spleen. It has been estimated with the help of resistant and sensitive bacilli that the relapses were due in most of the cases to the regrowth of one or very few bacilli, giving a clone. It seems that the C3H strain of mice, known to carry the Bcg-r allele of the Bcg gene, might be less able to develop a specific acquired resistance capable of stopping the delayed development of a highly virulent strain of mycobacteria.
UR - http://www.scopus.com/inward/record.url?scp=0024315088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024315088&partnerID=8YFLogxK
M3 - Article
C2 - 2502336
AN - SCOPUS:0024315088
SN - 0009-9104
VL - 76
SP - 458
EP - 462
JO - Clinical and Experimental Immunology
JF - Clinical and Experimental Immunology
IS - 3
ER -